Markets

IGC Pharma Receives Patent From Canadian Intellectual Property Office Covering Composition Of IGC-AD1 Therapy For Agitation In Alzheimer

Nov 5, 2026 · 10:21 AM ET· updated 1h ago

IGC Pharma, Inc. (NYSE:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare

Why It Matters

IGC Pharma got official permission from Canada to protect their new Alzheimer's medicine. This shows their treatment idea has real potential and they're moving forward seriously.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IGC0.19

-0.01 (-4.10%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.